Axonics® is dedicated to improving the quality of life of people suffering from bladder and bowel dysfunction, conditions that impact the lives of tens of millions of adults globally. The Company’s products include the Axonics Sacral Neuromodulation System designed to treat overactive bladder and fecal incontinence and the Bulkamid® hydrogel designed to treat women with stress urinary incontinence. For more information, visit www.axonics.com and www.bulkamid.com.
Axonics, Inc. (Nasdaq: AXNX) is headquartered in Irvine, California.
Axonics, Inc. (Nasdaq: AXNX) is headquartered in Irvine, California.
Location: United States, California, Irvine
Employees: 201-500
Phone: +1 877-929-6642
Founded date: 2013
Investors 1
| Date | Name | Website |
| - | Longitude ... | longitudec... |
Mentions in press and media 14
| Date | Title | Description |
| 18.11.2024 | The Future of Medtech: Leadership Changes and Data-Driven Innovations | The medical technology landscape is evolving rapidly. New leaders are stepping in, and data is becoming the lifeblood of innovation. This is a time of transformation, where the right leadership can steer companies toward success, and data c... |
| 18.11.2024 | Boston Scientific Closes Acquisition of Axonics | Boston Scientific Corporation (NYSE: BSX), a Marlborough, MA-based medical solutions provider, announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercializa... |
| 18.11.2024 | SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors | TEL AVIV, Israel, Nov. 18, 2024 /PRNewswire/ -- SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. Cohen to serve as its chairman of ... |
| 09.01.2024 | Why Carta’s public battle might be a private markets nightmare | To say the Carta news that broke over the weekend has caused a furor in the startup world is an understatement. The accusation that the cap table management and software unicorn was using customers’ confidential data to bolster its own busi... |
| 08.01.2024 | Boston Scientific Continues Buying Spree with $3.7B Axonics Acquisition | Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat urinary and bowel dysfunction, for $71 in cash... |
| 17.11.2021 | Deloitte Fast 500: Medical device company takes the top spot but software continues to dominate the top 10 | For the 26th straight year, software companies continued to dominate the Deloitte Technology Fast 500, but biotech and medical device companies also captured top spots. Axonics (Nasdaq: AXNX), a medical technology company, topped the 2021 l... |
| 05.11.2021 | Corporate Presentation | Investor Presentation November 2021 | Nasdaq: AXNX Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historic... |
| 06.05.2021 | Axonics® Reports First Quarter 2021 Financial Results | Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the first quarter ended March 3... |
| 25.02.2021 | Axonics® Reports Fourth Quarter and Fiscal Year 2020 Results | Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today re... |
| 23.09.2020 | Healthcare VC Firm Longitude Capital Closes $585M Fund | What You Should Know: – Healthcare venture capital firm Longitude Capital announces the close of its $585M Longitude Venture Partners IV, L.P. (“LVP4”) fund to invest in transformative healthcare companies. – LVP4 will invest opportunistica... |
Show more